All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
More information on our cookie policy.
BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Special reports
Artificial intelligence
Coronavirus
Diagnosing and tracking COVID-19
Drugs to Watch 2020
The next pandemic
Premium reports
BioWorld Financings Reports
Disease Forecast Reports
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Sunday, April 18, 2021
Home
» First patient dosed in phase II study of OTX-DED for short-term treatment of dry eye disease
First patient dosed in phase II study of OTX-DED for short-term treatment of dry eye disease
March 2, 2021
No Comments
Article reprints
Source:
https://science.bioworld.com/ddn/article.do?id=176748
BioWorld Science
Related Articles
First patient dosed in a phase II study of ensovibep for the treatment of COVID-19
First patient dosed in phase II study of ABP-450 as treatment of cervical dystonia
